Opus Genetics (IRD) Leases (2019 - 2020)
Opus Genetics (IRD) reported Leases of $106126.0 for Q3 2020, down 54.63% year-over-year from $233936.0 in Q4 2019, and down 23.91% on a QoQ basis from $139477.0 in Q2 2020.
Opus Genetics (IRD) has 2 years of Leases data on file, last reported at $106126.0 in Q3 2020.
- Quarterly Leases fell 54.63% year-over-year to $106126.0 in Q3 2020, while the trailing twelve-month figure through Sep 2020 was $106126.0 (down 54.63% YoY) and the FY2019 annual result came in at $203348.0, changed N/A from the prior year.
- Leases declined to $106126.0 in Q3 2020 per IRD's latest filing, from $139477.0 in the prior quarter.
- Across five years, Leases topped out at $303096.0 in Q1 2019 and bottomed at $106126.0 in Q3 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 83,048.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 61,822.50 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 285.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.69 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 189.30 Mn |
| 10 | Opus Genetics | 357.99 Mn | 298.03 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 106,126.00 |
| Jun 30, 2020 | 139,477.00 |
| Mar 31, 2020 | 171,870.00 |
| Dec 31, 2019 | 203,348.00 |
| Sep 30, 2019 | 233,936.00 |
| Jun 30, 2019 | 263,658.00 |
| Mar 31, 2019 | 303,096.00 |